Biosimilar Antibodies

Inotuzumab Biosimilar – Anti-CD22 mAb – Research Grade, ProteoGenix, PX-TA1185

Description of Inotuzumab Biosimilar - Anti-CD22 mAb - Research Grade Introduction Inotuzumab Biosimilar, also known as Anti-CD22 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original drug Inotuzumab Ozogamicin. It is a targeted therapy that specifically binds to the CD22 protein, which is overexpressed on the surface of certain cancer cells. In this article, we will explore the structure, activity, and potential applications of Inotuzumab Biosimilar as a research-grade antibody. Structure of Inotuzumab Biosimilar Inotuzumab Biosimilar is a recombinant, chimeric monoclonal antibody that is composed of both human and murine components. It is composed of two heavy chains and two light chains, each containing a variable region that specifically binds to the CD22 protein. The constant regions of the antibody are derived from human IgG1, making it less immunogenic and more suitable for use in humans. The antibody has a molecular weight of approximately 150 kDa. Activity of Inotuzumab Biosimilar The primary mechanism of action of Inotuzumab Biosimilar is through its binding to the CD22 protein. CD22 is a B-cell receptor that is expressed on the surface of B-cell lymphomas and leukemias. By binding to CD22, Inotuzumab Biosimilar targets and delivers a cytotoxic agent, calicheamicin, to the cancer cells. This results in the destruction of the cancer cells and inhibits their growth and proliferation. In addition to its direct cytotoxic effects, Inotuzumab Biosimilar also has immunomodulatory effects. It has been shown to increase the activity of natural killer cells and enhance their ability to kill cancer cells. This can further enhance the efficacy of the antibody in treating cancer. Applications of Inotuzumab Biosimilar Inotuzumab Biosimilar is currently being studied as a potential treatment for various types of B-cell malignancies, including non-Hodgkin’s lymphoma and acute lymphoblastic leukemia. It is being evaluated as a single agent and in combination with other chemotherapeutic agents. As a research-grade antibody, Inotuzumab Biosimilar can also be used in laboratory studies to further understand the mechanisms of action and potential applications of this targeted therapy. It can also be used to develop new assays and diagnostic tools for detecting CD22 expression in cancer cells. Conclusion Inotuzumab Biosimilar, also known as Anti-CD22 mAb, is a monoclonal antibody that specifically targets the CD22 protein on the surface of cancer cells. Its unique structure and mechanism of action make it a promising treatment option for B-cell malignancies. As a research-grade antibody, it also has potential applications in laboratory studies and diagnostic tools. Further research and clinical trials are needed to fully understand the potential of Inotuzumab Biosimilar in treating cancer.

Insulin eflivet Biosimilar – Research Grade, ProteoGenix, PX-TA2486-100

Intetumumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade, ProteoGenix, PX-TA1230

Description of Intetumumab Biosimilar - Anti-ITGAV_ITGB3 mAb - Research Grade Introduction: Intetumumab Biosimilar is a monoclonal antibody (mAb) that targets the integrin alpha V beta 3 (ITGAV_ITGB3) receptor. It is a research grade antibody that has shown promising results in pre-clinical studies and is being developed as a potential therapeutic agent for various diseases. Structure of Intetumumab Biosimilar: Intetumumab Biosimilar is a humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for its specificity towards the ITGAV_ITGB3 receptor. Activity of Intetumumab Biosimilar: The main activity of Intetumumab Biosimilar is to bind to the ITGAV_ITGB3 receptor, which is a cell surface receptor that plays a crucial role in cell adhesion, migration, and proliferation. This receptor is overexpressed in various types of cancer cells, making it an attractive therapeutic target. By binding to the ITGAV_ITGB3 receptor, Intetumumab Biosimilar blocks its activity and inhibits the growth and spread of cancer cells. Application of Intetumumab Biosimilar: 1. Cancer treatment: Intetumumab Biosimilar has shown promising results in pre-clinical studies as a potential treatment for various types of cancer. It has been shown to inhibit the growth and spread of cancer cells by targeting the ITGAV_ITGB3 receptor. This makes it a potential therapeutic option for cancers such as melanoma, breast cancer, and prostate cancer. 2. Angiogenesis inhibition: Intetumumab Biosimilar has also been studied for its ability to inhibit angiogenesis, which is the formation of new blood vessels. Angiogenesis plays a crucial role in the growth and spread of cancer, and by targeting the ITGAV_ITGB3 receptor, Intetumumab Biosimilar can potentially inhibit this process. 3. Rheumatoid arthritis: The ITGAV_ITGB3 receptor has been implicated in the development of rheumatoid arthritis, a chronic inflammatory disease that affects the joints. By targeting this receptor, Intetumumab Biosimilar has shown potential in reducing inflammation and joint damage in pre-clinical studies. 4. Osteoporosis: Intetumumab Biosimilar has also been studied for its potential in treating osteoporosis, a condition characterized by weak and brittle bones. The ITGAV_ITGB3 receptor has been found to play a role in bone remodeling, and by targeting it, Intetumumab Biosimilar can potentially improve bone density and strength. 5. Other diseases: Apart from the above-mentioned applications, Intetumumab Biosimilar is also being studied for its potential in other diseases such as psoriasis, atherosclerosis, and diabetic retinopathy. The ITGAV_ITGB3 receptor has been found to play a role in the pathogenesis of these diseases, and by targeting it, Intetumumab Biosimilar can potentially provide therapeutic benefits. Conclusion: Intetumumab Biosimilar is a promising research grade antibody that targets the ITGAV_ITGB3 receptor. Its ability to inhibit the growth and spread of cancer cells and its potential in treating other diseases make it a valuable therapeutic option. Further clinical studies are needed to fully understand the potential of Intetumumab Biosimilar and its role in the treatment of various diseases.

Ipsoprubart Biosimilar – Research Grade, ProteoGenix, PX-TA2488-100

Isatuximab Biosimilar – Anti-CD38 mAb – Research Grade, ProteoGenix, PX-TA1377

Description of Isatuximab Biosimilar - Anti-CD38 mAb - Research Grade General information on Anti-CD38[Homo sapiens] (Isatuximab) Monoclonal Antibody Isatuximab is a humanized monoclonal antibody derived from IgG1 that targets CD38, a glycoprotein found on the surface of some immune cells. CD38 is highly expressed by malignant plasma cells in multiple myeloma. Isatuximab is used to treat multiple myeloma. It is marketed under the trade name Sarclisa.

Iscalimab Biosimilar – Anti-CD40, TNFRSF5 mAb – Research Grade, ProteoGenix, PX-TA1503

Description of Iscalimab Biosimilar - Anti-CD40, TNFRSF5 mAb - Research Grade Introduction Iscalimab Biosimilar, also known as Anti-CD40, TNFRSF5 mAb, is a research grade monoclonal antibody that targets the CD40 protein, a member of the tumor necrosis factor receptor superfamily. This antibody has shown promising potential as a therapeutic agent in various diseases, making it a subject of extensive research and development. Structure of Iscalimab Biosimilar Iscalimab Biosimilar is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a high affinity and specificity for its target. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of 21 days. Mechanism of Action CD40 is a cell surface protein found on various immune cells, including B cells, dendritic cells, and macrophages. It plays a crucial role in the activation and differentiation of these immune cells, making it an attractive therapeutic target for various diseases. Iscalimab Biosimilar binds to CD40 and blocks its interaction with its ligand, CD154. This prevents the activation of downstream signaling pathways, leading to inhibition of immune cell activation and proliferation. Applications in Disease Treatment Iscalimab Biosimilar has shown promising results in preclinical and clinical studies as a potential treatment for various diseases. Here are some of its potential applications: 1. Autoimmune Diseases: CD40 plays a crucial role in the development of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Iscalimab Biosimilar has shown promising results in preclinical studies as a potential treatment for these diseases by inhibiting the activation of autoreactive immune cells. 2. Transplant Rejection: CD40-CD154 interaction is known to play a critical role in acute and chronic rejection of transplanted organs. Iscalimab Biosimilar has shown potential in preventing transplant rejection by blocking this interaction and reducing the activation of immune cells. 3. Cancer: CD40 is also expressed on the surface of tumor cells and has been linked to tumor growth and survival. Iscalimab Biosimilar has shown promising results in preclinical studies as a potential treatment for various cancers, including lymphoma, leukemia, and solid tumors, by inhibiting the activation of immune cells and promoting tumor cell death. 4. Infectious Diseases: CD40 is involved in the immune response against various infectious agents, including viruses and bacteria. Iscalimab Biosimilar has shown potential in enhancing the immune response against these pathogens by blocking CD40 and promoting the activation of immune cells. Conclusion Iscalimab Biosimilar is a research grade monoclonal antibody that targets the CD40 protein and has shown promising results as a potential treatment for various diseases. Its unique mechanism of action and potential applications make it a subject of extensive research and development. Further studies and clinical trials are needed to fully understand the therapeutic potential of Iscalimab Biosimilar and its role in the treatment of various diseases.

Iscastobart Biosimilar – Research Grade, ProteoGenix, PX-TA2493-100

Itolizumab Biosimilar – Anti-CD6 mAb – Research Grade, ProteoGenix, PX-TA1246

Description of Itolizumab Biosimilar - Anti-CD6 mAb - Research Grade General information on Anti-CD6[Homo sapiens] (Itolizumab) Monoclonal Antibody Itolizumab is investigated for the treatment of patients Hospitalized With COVID-19.

Ixekizumab Biosimilar – Anti-IL17A mAb – Research Grade, ProteoGenix, PX-TA1022

Description of Ixekizumab Biosimilar - Anti-IL17A mAb - Research Grade General information about Ixekizumab Recombinant monoclonal antibody to IL17A. Ixekizumab is a humanized monoclonal antibody used in the treatment of autoimmune diseases. This product is for research use only.

Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb – Research Grade, ProteoGenix, PX-TA1854

Description of Izenivetmab Biosimilar - Anti-NGFB (Canine) mAb - Research Grade Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb: A Powerful Antibody Targeting NGFB for Canine Therapy Introduction Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb is a novel monoclonal antibody (mAb) that specifically targets the nerve growth factor beta (NGFB) in canines. This biosimilar antibody is derived from the original Izenivetmab, which has been successfully used in human therapy for various diseases. With its high specificity and potency, Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb shows great potential as a therapeutic agent for canine diseases involving NGFB. Structure of Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb is a fully humanized IgG1 antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for recognizing and binding to NGFB, while the constant regions mediate effector functions such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Activity of Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb NGFB is a neurotrophic factor that plays a crucial role in the development and maintenance of the nervous system in canines. It is also involved in various physiological processes, including pain perception, inflammation, and immune response. However, overexpression of NGFB has been linked to several pathological conditions, such as chronic pain, neuropathies, and autoimmune diseases. Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb specifically binds to NGFB and inhibits its activity, thereby reducing the symptoms associated with NGFB-related diseases. Application of Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb has potential applications in various canine diseases, including chronic pain, osteoarthritis, and autoimmune disorders. Chronic pain is a common condition in aging canines, and NGFB has been implicated in its development and maintenance. By targeting NGFB, Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb can provide relief from chronic pain in canines. Osteoarthritis is another prevalent condition in canines, especially in older dogs. NGFB has been found to be involved in the pathogenesis of osteoarthritis by promoting inflammation and cartilage degradation. Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb can potentially slow down the progression of osteoarthritis by inhibiting NGFB activity and reducing inflammation. Autoimmune diseases, such as immune-mediated hemolytic anemia and immune-mediated thrombocytopenia, are also potential targets for Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb. NGFB has been shown to play a role in the pathogenesis of these diseases by promoting autoantibody production and inflammation. By blocking NGFB, Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb can potentially mitigate the symptoms of these autoimmune disorders. Conclusion In summary, Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb is a promising antibody therapy for canines targeting NGFB. Its specific binding to NGFB and inhibition of its activity make it a potential treatment option for various canine diseases, including chronic pain, osteoarthritis, and autoimmune disorders. Further research and clinical trials are needed to fully explore the therapeutic potential of Izenivetmab Biosimilar – Anti-NGFB (Canine) mAb in the veterinary field.